A case of antilaminin 332 mucous membrane pemphigoid showing a blister on the bulbar conjunctiva and a unique epitope on the α3 subunit

Hashimoto, Takashi; Dainichi, Teruki; Ohyama, Bungo; Hamada, Takahiro; Ishii, Norito; Sato, Noriaki; Tanigawa, Osamu; Nakayama, Jitichiro; Amano, Sadao; Nishiyama, Toshio; Karashima, Tadashi; Nakama, Takekuni; Yasumoto, Shinichiro

doi:10.1111/j.1365-2133.2010.09648.x

Cited by 7 publications

(9 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Our patient demonstrated antibodies to both α3 and β3 subunits. The combination of prednisone and dapsone has been reported to be effective in controlling anti-laminin-332 MMP, 29,30 as was also the outcome in our patient.…”

Section: Discussionsupporting

confidence: 58%

Anti–Laminin-332 Mucous Membrane Pemphigoid Developing After a Diphtheria Tetanus Vaccination

et al. 2013

View full text Add to dashboard Cite

accine administration is an effective tool to prevent infectious diseases, but its powerful stimulus on the immune system has generated the fear of exacerbating preexisting autoimmune diseases or inducing autoimmune disorders in otherwise healthy individuals.1 Bullous pemphigoid (BP) is the most frequent autoimmune blistering skin disease. It affects predominantly elderly individuals but has also been reported in children. The etiologic characteristics of BP are unknown, but there have been 26 BP cases suspected of having been induced by vaccinations (Table). [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] In all of the postvaccination BP cases in which immunoblotting and/or enzyme-linked immunosorbent assay (ELISA) studies were performed, the target antigens were found to be BP180 and/or BP230. 3,8,12,16,17 We report a unique case of mucous membrane pemphigoid (MMP) that developed acutely in a 29-yearold man 2 days after he received a diphtheria tetanus (DT) vaccination. The results of laboratory studies were compatible with anti-laminin-332 MMP, which to our knowledge has not been previously described following vaccination. Report of a CaseAn otherwise healthy 29-year-old man was admitted to our department as a result of a sudden mucocutaneous eruption of blisters that occurred 2 days after receiving a DT vaccine for a traumatic skin cut. There were no available medical records of previous DT vaccinations, although the pediatric population in Israel is vaccinated regularly several times during childhood. The patient did not have a history of skin diseases or allergies to medications. The superficial cut was 1.5 cm long. It was treated with povidone-iodine solution and closed with adhesive surgical tape strips. There was no wound infection, and the patient did not receive any systemic antibiotics. On physical examination, there were tense blisters along with flaccid blisters and erosions on the face, inguinal area, and lower abdomen ( Figure 1). There were also widespread erosions on the oral mucosa (Figure 1). The Nikolsky sign was absent, and the rest of the physical examination had normal results. Histopathologic analysis of a skin blister revealed a subepidermal blister with complete epidermal-dermal separation and a sparse mononuclear cell infiltrate in the papillary dermis (Figure 2A and B). Immunohistochemical staining demonstrated type IV collagen on the dermal floor of the split ( Figure 2C). Direct immunofluorescence microscopy showed linear deposits of IgG and C3 along the basement membrane zone. An indirect immunofluorescence test on the patient's serum, which was performed on monkey esophagus, revealed linear deposits of IgG along the basement membrane zone with a titer of 1:160. Indirect immunofluorescence microscopy performed on 1M so-IMPORTANCE Bullous pemphigoid (BP) has been previously described to develop after vaccination in 26 patients. Immunoblotting or enzyme-linked immunosorbent assays (ELISAs), which were performed for 7 of these patients, have always shown circ...

show abstract

Section: Discussionsupporting

confidence: 58%

Anti–Laminin-332 Mucous Membrane Pemphigoid Developing After a Diphtheria Tetanus Vaccination

et al. 2013

View full text Add to dashboard Cite

show abstract

“…2 While an inherently difficult task, disparities are noted in the WMLEM. 3 Herein, this letter utilizes Global Burden of Disease (GBD), 3 Treatment of Skin Disease (5th edn) (TSD) 4 and Evidence-Based Dermatology (3rd edn) (EBD) 5 data, and expert opinion to explore the paucities of the current WMLEM. The recent 21st WMLEM (June 2019 edition) was retrieved from the World Health Organization (WHO) website.…”

mentioning

confidence: 99%

“…2 Dermatological medicines (subsection 13) on the WMLEM 2019 were compared with a list of evidence-based treatments from TSD and EBD. 4,5 The 14 dermatological diagnoses from GBD 2017 include dermatitis, psoriasis, cellulitis, pyoderma, scabies, fungal skin diseases, viral skin diseases, acne vulgaris, alopecia areata, pruritus, urticaria, decubitus ulcer, melanoma and keratinocyte carcinoma. Disability-adjusted life years (DALYs), the sum of years of life lost to a disease plus the years lost to disability, were extracted.…”

mentioning

confidence: 99%

Clinical and immunological findings in 55 patients with anti‐laminin 332‐type mucous membrane pemphigoid

Qian

Natsuaki

et al. 2021

Br J Dermatol

Self Cite

View full text Add to dashboard Cite

“…BP230, a plakin family protein, and BP180 are major target antigens in bullous pemphigoid 7 . Laminin‐332 is a target antigen in antilaminin‐332 type mucous membrane pemphigoid 8 . Binding between laminin‐332 and its receptor α6β4 integrin transduces signals for keratinocyte functions, such as cell motility, cell adhesion, cell growth and apoptosis 7 .…”

mentioning

confidence: 99%

Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II

Fukuda

Tsuruta

Uchiyama

et al. 2011

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

A case of antilaminin 332 mucous membrane pemphigoid showing a blister on the bulbar conjunctiva and a unique epitope on the α3 subunit

Abstract: A case of antilaminin 332 mucous membrane pemphigoid showing a blister on the bulbar conjunctiva and a unique epitope on the a3 subunit Ó

Cited by 7 publications

References 7 publications

Anti–Laminin-332 Mucous Membrane Pemphigoid Developing After a Diphtheria Tetanus Vaccination

Anti–Laminin-332 Mucous Membrane Pemphigoid Developing After a Diphtheria Tetanus Vaccination

Clinical and immunological findings in 55 patients with anti‐laminin 332‐type mucous membrane pemphigoid

Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II

Contact Info

Product

Resources

About